Vivacelle Bio

Vivacelle Bio

Biotechnology, 2242 W Harrison St Ste , Chicago, , 60612, Illinois, 20125, United States, 1-10 Employees

vivacellebio.com

  • twitter
  • LinkedIn

phone no Phone Number: 13*********

Who is VIVACELLE BIO

VIVACELLE BIO, Inc. is a developmental stage biotechnology company developing products utilizing nanoparticle technology. Their first product, VBI-1, a colloid non-blood volume expander a...

Read More

map
  • 2242 W Harrison St Ste 20125, Chicago, Illinois, 60612, United States Headquarters: 2242 W Harrison St Ste 20125, Chicago, Illinois, 60612, United States
  • 2013 Date Founded: 2013
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from VIVACELLE BIO

Vivacelle Bio Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Vivacelle Bio

Answer: Vivacelle Bio's headquarters are located at 2242 W Harrison St Ste , Chicago, , 60612, Illinois, 20125, United States

Answer: Vivacelle Bio's phone number is 13*********

Answer: Vivacelle Bio's official website is https://vivacellebio.com

Answer: Vivacelle Bio's revenue is $1 Million to $5 Million

Answer: Vivacelle Bio's SIC: 2834

Answer: Vivacelle Bio has 1-10 employees

Answer: Vivacelle Bio is in Biotechnology

Answer: Vivacelle Bio contact info: Phone number: 13********* Website: https://vivacellebio.com

Answer: VIVACELLE BIO, Inc. is a developmental stage biotechnology company developing products utilizing nanoparticle technology. Their first product, VBI-1, a colloid non-blood volume expander appears to be safer and far more effective than the standard treatment for hypovolemia in animal studies and received green light from FDA to start a phase IIa clinical trial in hypovolemia due to blood loss. The immediate other product in the pipeline is VBI-S, targeting hypovolemia due to sepsis/septic shock. Hypovolemia results from inadequate fluid volume in the blood vessels, causes the death of over a one million people globally each year. Major causes for fluid loss are trauma, surgery, shock, sepsis, severe diarrhea and burns. Inadequate circulating volume impairs tissue perfusion and oxygenation leading to cell injury and death. Rapid volume replacement and re-establishment of normal blood pressure are essential for survival. Currently available options of fluid replacements are non-blood volume expanders (colloids and crystalloids), blood products and blood substitutes. They have proven to be impractical and have the potential for significant negative adverse effects. VBI-1, represents a new paradigm in fluid resuscitation, safely restoring blood vessel volume and reversing the effects of hypovolemia. VBI-1 also modulates Nitric Oxide (a potent vasodilator that drops the blood pressure and a precursor to highly highly toxic mediators), reduces reperfusion injury, inhibits the inflammatory response, clears the endotoxin, metabolizes to naturally-occurring components and acts as an energy source. In addition, it can be loaded with readily available oxygen.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access